STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform - Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics
Boehringer Ingelheim
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Friday, December 11, 2020 12:20PM IST (6:50AM GMT)
Ingelheim, Germany & Basel, Switzerland:
Acquisition will add another key dimension to Boehringer Ingelheim’s focus on patients with difficult-to-treat solid tumors
NBE-Therapeutics’pipeline is based on its innovative next generation antibody-drug conjugate (ADC) technology platform
NBE-Therapeutics’will remain at its campus in Basel, Switzerland and operate as a new site within Boehringer Ingelheim’s R&D network
Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived